Equillium, Inc.
2223 Avenida de la Playa
Suite 108
La Jollla
California
92037
United States
130 articles about Equillium, Inc.
-
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
5/13/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced financial results for the first quarter 2021, and provided an update on its clinical development programs.
-
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
5/13/2021
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease has been accepted for oral presentation at EHA2021 Virtual Congress.
-
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
4/27/2021
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients
-
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
3/30/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced favorable topline data from the Type A group of the EQUALISE study in patients with systemic lupus erythematosus (SLE)
-
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
3/24/2021
Cash runway into the second half of 2023 Announced positive interim data from EQUATE study in aGVHD Multiple data and regulatory catalysts in 2021
-
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
3/15/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive data supporting the role of itolizumab as a potential treatment for acute graft-versus-host disease (aGVHD).
-
Equillium to Present at the H.C. Wainwright Global Life Sciences Conference
3/2/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences Conference.
-
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2/18/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22 – 26, 2021.
-
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
2/12/2021
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a first-line treatment for acute graft-versus-host disease (aGVHD).
-
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
2/9/2021
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equillium’s board of directors, effective Thursday, February 4, 2021.
-
Equillium Announces Closing of $30 Million Registered Direct Offering
2/5/2021
Equillium, Inc. announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock.
-
Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.
-
There are severely limited therapeutic options for immuno-inflammatory diseases such as acute graft vs. host disease (aGVHD), lupus and asthma.
-
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
-
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
1/22/2021
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.
-
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
1/5/2021
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference
-
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical OfficerEquillium Further Strengthens Management Team with Additional Executive Hires
12/21/2020
Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma (recently acquired by Sanofi) where she was chief medical officer focused on developing treatments for immu
-
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition
12/7/2020
Studies further support itolizumab’s potential as treatment for aGVHD patients
-
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020
11/30/2020
Equillium, Inc. (Nasdaq: EQ), today announced that it will host a virtual Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to 12:00 p.m. ET.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.